Skip to NavigationSkip to content

Pharmafile.com's weekly COVID-19 news round-up

Published on 01/07/20 at 11:31am
Photo by CDC

COVID-19 vaccines dominate this week’s news cycle, with Vaxart announcing the selection of its lead candidate for COVID-19 by Operation Warp Speed, while China’s military have received approval to use a new vaccine candidate and AstraZeneca has continued to build its manufacturing capacity to deliver its coronavirus vaccine.

In other news, the National Institutes of Health had its funding cut from a research project into bat coronavirus while Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.

1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells CongressPublished 25/06/20

The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.

2. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnershipPublished 25/06/20

AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.

3. Vaxart announces its COVID-19 vaccine has been selected by US Operation Warp Speed programmePublished on 29/06/20

Vaxart has announced the selection of its lead vaccine candidate for COVID-19 by Operation Warp Speed, a program to find a vaccine for the US by the end of the year.

4. China’s COVID-19 vaccine candidate approved for military usePublished 29/06/20

China’s military have received approval to use a new vaccine candidate for coronavirus after clinical trials proved it was safe and showed some efficacy.

5. Gilead facing criticism for charging $2,340 for remdesivirPublished on 30/06/20

Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches